Brain delivery of camptothecin by means of solid lipid nanoparticles: Formulation design, in vitro and in vivo studies

International Journal of Pharmaceutics

Volumn 439, Issue 1-2, 2012, Pages 49-62

  Martins, Susana ^a,b,c,d   Tho, Ingunn ^b   Reimold, Isolde ^c   Fricker, Gert ^c   Souto, Eliana ^e   Ferreira, Domingos ^a   Brandl, Martin ^b,f  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF TROMSØ   (Norway)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

^e UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^f UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Brain capillary endothelial cells (BCEC); Brain delivery; Camptothecin; Multivariate analysis; Solid lipid nanoparticles (SLN); Surfactants

Indexed keywords

CAMPTOTHECIN; SOLID LIPID NANOPARTICLE; TETRAZOLIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; BRAIN TUMOR; CAPILLARY ENDOTHELIUM; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; ENCAPSULATION; FLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PARTICLE SIZE; PH; PHYSICAL CHEMISTRY; PLASMA; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN; CAMPTOTHECIN; CELL LINE; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG STABILITY; LIPIDS; MALE; MICE; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, WISTAR; SURFACE-ACTIVE AGENTS; SWINE;

EID: 84867836553     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.09.054     Document Type: Article

References (62)

1. N.J. Abbott, A.A.K. Patabendige, D.E.M. Dolman, S.R. Yusof, and D.J. Begley Structure and function of the blood-brain barrier Neurobiol. Dis. 37 2010 13 25
2. F. Bokstein, S. Shpigel, and D.T. Blumenthal Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors Cancer 112 2008 2267 2273
3. M. Brangi, T. Litman, M. Ciotti, K. Nishiyama, G. Kohlhagen, and C. Takimoto S.E. Bates Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells Cancer Res. 59 1999 5938 5946
4. H. Bunjes, M. Drechsler, M.H. Koch, and K. Westesen Incorporation of the model drug ubidecarenone into solid lipid nanoparticles Pharm. Res. 18 2001 287 293
5. H. Bunjes, M.H. Koch, and K. Westesen Influence of emulsifiers on the crystallization of solid lipid nanoparticles J. Pharm. Sci. 92 2003 1509 1520
6. H. Bunjes, M.H.J. Koch, and K. Westesen Effect of particle size on colloidal solid triglycerides Langmuir 16 2000 5234 5241
7. H. Bunjes, and T. Unruh Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering Adv. Drug Deliv. Rev. 59 2007 379 402
8. T.G. Burke, A.K. Mishra, M.C. Wani, and M.E. Wall Lipid bilayer partitioning and stability of camptothecin drugs Biochemistry 32 1993 5352 5364
9. Y. Çirpanli, E. Allard, C. Passirani, E. Bilensoy, L. Lemaire, S. Çaliş, and J.-P. Benoit Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model Int. J. Pharm. 403 2011 201 206
10. Y. Cirpanli, E. Allard, C. Passirani, E. Bilensoy, L. Lemaire, S. Calis, and J.P. Benoit Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model Int. J. Pharm. 403 2011 201 206
11. J. Fassberg, and V.J. Stella A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues J. Pharm. Sci. 81 1992 676 684
12. F. Fleury, A. Ianoul, M. Berjot, A. Feofanov, A.J. Alix, and I. Nabiev Camptothecin-binding site in human serum albumin and protein transformations induced by drug binding FEBS Lett. 411 1997 215 220
13. K. Gao, and X. Jiang Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles Int. J. Pharm. 310 2006 213 219
14. M. Gaumet, A. Vargas, R. Gurny, and F. Delie Nanoparticles for drug delivery: the need for precision in reporting particle size parameters Eur. J. Pharm. Biopharm. 69 2008 1 9
15. J.A. Gottlieb, A.M. Guarino, J.B. Call, V.T. Oliverio, and J.B. Block Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880) Cancer Chemother. Rep. 54 1970 461 470
16. Z.R. Huang, S.C. Hua, Y.L. Yang, and J.Y. Fang Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion Acta Pharmacol. Sin. 29 2008 1094 1102
17. M.D. Joshi, and R.H. Müller Lipid nanoparticles for parenteral delivery of actives Eur. J. Pharm. Biopharm. 71 2009 161 172
18. O.M. Koo, I. Rubinstein, and H. Onyuksel Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine Nanomedicine 1 2005 77 84
19. J. Kreuter Nanoparticulate systems for brain delivery of drugs Adv. Drug Deliv. Rev. 47 2001 65 81
20. J. Kreuter, V.E. Petrov, D.A. Kharkevich, and R.N. Alyautdin Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles J. Control. Release 49 1997 81 87
21. J. Kreuter, D. Shamenkov, V. Petrov, P. Ramge, K. Cychutek, C. Koch-Brandt, and R. Alyautdin Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier J. Drug Target 10 2002 317 325
22. P.R. Lockman, J.M. Koziara, R.J. Mumper, and D.D. Allen Nanoparticle surface charges alter blood-brain barrier integrity and permeability J. Drug Target 12 2004 635 641
23. Loubnan, V.; Nasser, S.; 2010. A guide on intravenous drug compatibilities based on their pH Pharmacie Globale (IJCP). 5.
24. G. Lukowski, J. Kasbohm, P. Pflegel, A. Illing, and H. Wulff Crystallographic investigation of cetylpalmitate solid lipid nanoparticles Int. J. Pharm. 196 2000 201 205
25. A. Mahringer, J. Delzer, and G. Fricker A fluorescence-based in vitro assay for drug interactions with breast cancer resistance protein (BCRP, ABCG2) Eur. J. Pharm. Biopharm. 72 2009 605 613
26. H. Martens, and M. Martens Modified Jack-knife estimation of parameter uncertainty in bilinear modelling by partial least squares regression (PLSR) Food Qual. Prefer. 11 2000 5 16
27. S. Martins, S. Costa-Lima, T. Carneiro, A. Cordeiro-da-Silva, E.B. Souto, and D.C. Ferreira Solid lipid nanoparticles as intracellular drug transporters: an investigation of the uptake mechanism and pathway Int. J. Pharm. 430 2012 216 227
28. S. Martins, I. Tho, D.C. Ferreira, E.B. Souto, and M. Brandl Physicochemical properties of lipid nanoparticles: effect of lipid and surfactant composition Drug Dev. Ind. Pharm. 37 2011 815 824
29. S. Martins, I. Tho, E.B. Souto, D. Ferreira, and M. Brandl Multivariate design for the evaluation of lipid and surfactant composition effect for optimisation of lipid nanoparticles Eur. J. Pharm. Sci. 45 2012 613 623
30. S.M. Martins, T. Wendling, V.M.F. Gonçalves, B. Sarmento, and D.C. Ferreira Development and validation of a simple reversed-phase HPLC method for the determination of camptothecin in animal organs following administration in solid lipid nanoparticles J. Chromatogr. B 880 2012 100 107
31. K.H. Min, K. Park, Y.-S. Kim, S.M. Bae, S. Lee, H.G. Jo, and I.C. Kwon Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy J. Control. Release 127 2008 208 218
32. C.G. Moertel, A.J. Schutt, R.J. Reitemeier, and R.G. Hahn Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer Cancer Chemother. Rep. 56 1972 95 101
33. S.M. Moghimi, A.C. Hunter, and J.C. Murray Long-circulating and target-specific nanoparticles: theory to practice Pharmacol. Rev. 53 2001 283 318
34. F.M. Muggia, P.J. Creaven, H.H. Hansen, M.H. Cohen, and O.S. Selawry Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies Cancer Chemother. Rep. 56 1972 515 521
35. R.H. Müller, K. Mader, and S. Gohla Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the sate of the art Eur. J. Pharm. Biopharm. 50 2000 161 177
36. A.T. Nies The role of membrane transporters in drug delivery to brain tumors Cancer Lett. 254 2007 11 29
37. M. Ott, M. Huls, M.G. Cornelius, and G. Fricker St. John's Wort constituents modulate P-glycoprotein transport activity at the blood-brain barrier Pharm. Res. 27 2010 811 822
38. W.M. Pardridge Alzheimer's disease drug development and the problem of the blood-brain barrier Alzheimer's Dement. 5 2009 427 432
39. N. Pongcharoenkiat, G. Narsimhan, R.T. Lyons, and S.L. Hem The effect of surface charge and partition coefficient on the chemical stability of solutes in O/W emulsions J. Pharm. Sci. 91 2002 559 570
40. M. Potmesil Camptothecins: from bench research to hospital wards Cancer Res. 54 1994 1431 1439
41. V.K. Puduvalli, P. Giglio, M.D. Groves, K.R. Hess, M.R. Gilbert, S. Mahankali, and W.K. Yung Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme Neuro. Oncol. 10 2008 216 222
42. N.J. Rahier, B.M. Eisenhauer, R. Gao, S.H. Jones, and S.M. Hecht Water-soluble camptothecin derivatives that are intrinsic topoisomerase I poisons Org. Lett. 6 2004 321 324
43. I. Reimold, D. Domke, J. Bender, C.A. Seyfried, H.E. Radunz, and G. Fricker Delivery of nanoparticles to the brain detected by fluorescence microscopy Eur. J. Pharm. Biopharm. 70 2008 627 632
44. L.P. Rivory, and J. Robert Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives Pharmacol. Therapeut. 68 1995 269 296
45. A.M. Saetern, N.B. Nguyen, A. Bauer-Brandl, and M. Brandl Effect of hydroxypropyl-beta-cyclodextrin-complexation and pH on solubility of camptothecin Int. J. Pharm. 284 2004 61 68
46. M. Santisteban, J.C. Buckner, J.M. Reid, W. Wu, B.W. Scheithauer, M.M. Ames, and E. Galanis Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results J. Neurooncol. 92 2009 165 175
47. M.A. Schubert, and C.C. Muller-Goymann Characterisation of surface-modified solid lipid nanoparticles (SLN): influence of lecithin and nonionic emulsifier Eur. J. Pharm. Biopharm. 61 2005 77 86
48. P. Shahgaldian, E. Da Silva, A.W. Coleman, B. Rather, and M.J. Zaworotko Para-acyl-calix-arene based solid lipid nanoparticles (SLNs): a detailed study of preparation and stability parameters Int. J. Pharm. 253 2003 23 38
49. A. Shenderova, T.G. Burke, and S.P. Schwendeman The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins Pharm. Res. 16 1999 241 248
50. E.B. Souto, and R.H. Muller Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes Handb. Exp. Pharmacol. 2010 115 141
51. P.B. Storm, J.L. Moriarity, B. Tyler, P.C. Burger, H. Brem, and J. Weingart Polymer delivery of camptothecin against 9L gliosarcoma: release, distribution, and efficacy J. Neurooncol. 56 2002 209 217
52. W. Tong, L. Wang, and M.J. D'Souza Evaluation of PLGA microspheres as delivery system for antitumor agent-camptothecin Drug Dev. Ind. Pharm. 29 2003 745 756
53. M. Üner, and G. Yener Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives Nanomedicine 2 2007 289 300
54. I. van Rooy, S. Cakir-Tascioglu, W. Hennink, G. Storm, R. Schiffelers, and E. Mastrobattista In vivo methods to study uptake of nanoparticles into the brain Pharm. Res. 28 2011 456 471
55. J.J. Vredenburgh, A. Desjardins, J.E. Herndon 2nd, J.M. Dowell, D.A. Reardon, J.A. Quinn, and H.S. Friedman Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma Clin Cancer Res. 13 2007 1253 1259
56. M. Watanabe, K. Kawano, K. Toma, Y. Hattori, and Y. Maitani In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin J. Control. Release. 127 2008 231 238
57. S. Wohlfart, A.S. Khalansky, S. Gelperina, D. Begley, and J. Kreuter Kinetics of transport of doxorubicin bound to nanoparticles across the blood-brain barrier J. Control. Release 154 2011 103 107
58. S. Yang, J. Zhu, Y. Lu, B. Liang, and C. Yang Body distribution of camptothecin solid lipid nanoparticles after oral administration Pharm. Res. 16 1999 751 757
59. S.C. Yang, L.F. Lu, Y. Cai, J.B. Zhu, B.W. Liang, and C.Z. Yang Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain J Control Release. 59 1999 299 307
60. S.C. Yang, L.F. Lu, Y. Cai, J.B. Zhu, B.W. Liang, and C.Z. Yang Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain J. Control. Release. 59 1999 299 307
61. S.C. Yang, and J.B. Zhu Preparation and characterization of camptothecin solid lipid nanoparticles Drug Dev. Ind. Pharm. 28 2002 265 274
62. A. zur Mühlen, C. Schwarz, and W. Mehnert Solid lipid nanoparticles (SLN) for controlled drug delivery - drug release and release mechanism Eur. J. Pharm. Biopharm. 45 1998 149 155